INDP (Indaptus Therapeutics) GF Value : $0.00 (As of Jul. 06, 2025)

View and export this data going back to 2021. Start your Free Trial

What is Indaptus Therapeutics GF Value?

As of today (2025-07-06), Indaptus Therapeutics's share price is $11.09. Indaptus Therapeutics's GF Value is $0.00. Therefore, Indaptus Therapeutics's Price-to-GF-Value for today is . Based on the relationship between the current stock price and the GF Value, GuruFocus believes Indaptus Therapeutics is Not Valued.

The GF Value represents the intrinsic value of a stock, determined using GuruFocus' proprietary methodology. The GF Value Line on our stock Summary page provides an estimate of the stock’s fair-trading value.

To calculate this value, GuruFocus follows these steps:

We analyze historical correlations between the stock price and key business performance metrics, such as revenue, earnings, cash flow, and book value.
We identify the metrics that have the strongest historical correlation with the stock price and determine the historical multiples at which the stock has traded relative to these metrics.
Using these historical multiples as a reference, we estimate the stock's fair value while accounting for future business growth. Adjustments may be made based on the company’s past returns and growth trends.

GuruFocus believes that the GF Value Line represents the fair value at which a stock should trade. Stock prices typically fluctuate around this line. If a stock’s price is significantly above the GF Value Line, it is considered overvalued, and its future returns are likely to be lower. Conversely, if the stock price is significantly below the GF Value Line, its future returns are likely to be higher.

Indaptus Therapeutics (NAS:INDP) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 ratings:

Posssible Evaluations	All-in-One Screener Examples (1)
Possible Value Trap, Think Twice	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (2)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (2)	Predictable High Quality Companies which are Significantly Undervalued

(1) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(2) A sufficient margin of safety exists only when the stock is undervalued.

Possible Value Trap, Think Twice companies are those that appear significantly undervalued based on their Price-to-GF-Value ratio, but whose fundamentals show signs of weakness.

Indicators that a company may be a value trap include:

    * Deteriorating Financial Health: A low Altman Z-scores indicates a higher risk of bankruptcy, or a low Piotroski F-Score.
    * Earnings Manipulation: A high Beneish M-score indicates potential earnings manipulation, raising concerns about the reliability of reported financials.
    * Stagnant or Declining Growth: Lack of revenue or earnings growth, or a recent slowdown, may signal limited future prospects.

Investors should conduct thorough due diligence, examining financial statements and growth indicators, to avoid falling into value traps.

Indaptus Therapeutics's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	11.09	/	0.00
	=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indaptus Therapeutics GF Value Related Terms

Thank you for viewing the detailed overview of Indaptus Therapeutics's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Indaptus Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Indaptus Therapeutics Inc (NAS:INDP) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

3 Columbus Circle, 15th Floor, New York, NY, USA, 10019

Website

https://www.indaptusrx.com

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

Executives

Glen R. Anderson	10 percent owner	3274 ROSS ROAD, PALO ALTO CA 94303
Roger J. Waltzman	officer: Chief Medical Officer	C/O JAGUAR ANIMAL HEALTH, INC., 201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105
Robert Martell	director	4 MAGUIRE ROAD, LEXINGTON MA 02421
Boyan Vesselinov Litchev	officer: Chief Medical Officer	13357 RUSSET LEAF LN., SAN DIEGO CA 92129
Jeffrey A Meckler	director, officer: Chief Executive Officer	740 BROADWAY, 9TH FLOOR, NEW YORK NY 10003
Walt Addison Linscott	officer: Chief Business Officer	1860 MONTREAL ROAD, TUCKER GA 30084
Michael James Newman	director, 10 percent owner, officer: Chief Scientific Officer	C/O INTEC PARENT, INC., 12 HARTOM ST., HAR HOTZVIM, JERUSALEM L3 9777512
Mark John Gilbert	director	13731 NORTHWOOD RD., NW, SEATTLE WA 98177
Brian O'callaghan	director	550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Hoonmo Lee	director, 10 percent owner	C/O INTEC PARENT, INC., 12 HARTOM ST., HAR HOTZVIM, JERUSALEM L3 9777512
Anthony J Maddaluna	director	PFIZER INC. ATTN CORPORATE SECRETARY, 235 RAST 42ND STREET, NEW YORK NY 10017
William B Hayes	director	231 MAPLE AVENUE, BURLINGTON NC 27215
Roger Pomerantz	director	711 HARVEST HILL ROAD, CHALFONT PA 18914
Hila Karah	director	9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
Nir Sassi	officer: Chief Financial Officer	3 ELUL STREET, APT. 6, MODIIN L3 7176397